Pharmaceutical Technology's Equipment and Machinery Trends Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Equipment and Machinery Trends Survey
The pharmaceutical industry plans moderate increases in spending for equipment and machinery in 2008. Investments include equipment for solid-dosage manufacturing, active pharmaceutical ingredients, and parenteral manufacturing.


Pharmaceutical Technology
Volume 3, Issue 32

Spending increases for 2008

More than one-third (36.4%) of respondents plan to spend more on pharmaceutical machinery and equipment in 2008 than in 2007, and more than a quarter (26.8%) plan to spend the same amount (see Figure 5). About 16.5% plan to spend less, and 20.3% do not know whether they plan to increase spending.


Figure 5.
For those companies that plan to increase spending in 2008, a critical question is how great the increases. For respondents whose companies plan to spend more in 2008 than in 2007, the mean planned increase in spending is 9.3%. The median increase is 4.1–6%.


Figure 6.
Figure 6 shows the percentage by which respondents say they will increase spending in 2008 compared with 2007. Almost 14% say their planned percentage increase will be less than 2%. Roughly one-third (34.0%) say the increase will be 2.1%–4%, and 30.1% say it will be between 4.1–6%. More than 20% (22.3%) report that their planned increases will be greater than 6% compared with 2007.

Of the respondents whose companies plan to increase their 2008 spending over 2007 levels, 66% say the planned increase is greater than their 2006–2007 increase, 30% say it is on par, and 4% say it is less.

Spending allocation in 2008

An important consideration in assessing spending habits is to determine the types of equipment for planned spending in 2008. Respondents most frequently plan to increase their spending on laboratory equipment (31.6%) and machinery for quality assurance and control (30.9%).

Roughly one-quarter of respondents say they will increase spending in 2008 in the following areas: process control and automation (27.9%), processing (27.9%), packaging (27.6%), API manufacturing (24.7%), cleanrooms (21.6%), and parenteral manufacturing (21.2%).

Solid-dosage manufacturing and environment control ranked as the lowest areas for planned spending in 2008. Only 19.6% of respondents said that they will increase spending for equipment and machinery for solid-dosage manufacturing in 2008, and 16.1% for environmental control.


Figure 7.
Figure 7 shows the areas in which respondents say they will spend the most in 2008. Roughly one-fifth (21.3%) say they plan to spend the most on manufacturing and processing equipment in 2008. Interestingly, although solid-dosage manufacturing was not a popular area for spending, it was one of the areas in which respondents said they plan to spend the most in 2008. Nearly 15% of respondents said that they plan to spend the most for machinery and equipment for solid-dosage manufacturing. Thirteen and one-half percent ranked API manufacturing as the area for their highest spending in 2008, and 13.1% did so for parenteral manufacturing.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here